These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21962389)

  • 1. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab.
    Ogata A; Umegaki N; Katayama I; Kumanogoh A; Tanaka T
    Joint Bone Spine; 2012 Jan; 79(1):85-7. PubMed ID: 21962389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
    Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse responses of the skin and nail lesions of psoriatic arthritis to an anti-interleukin-17A antibody and an anti-tumor necrosis factor-α antibody.
    Komatsu-Fujii T; Honda T; Otsuka A; Kabashima K
    J Dermatol; 2019 Nov; 46(11):e440-e441. PubMed ID: 31254299
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label Use of Tocilizumab in Psoriatic Arthritis: Case Series and Review of the Literature.
    Madureira P; Pimenta SS; Bernardo A; Brito JS; Bernardes M; Costa L
    Acta Reumatol Port; 2016; 41(3):251-255. PubMed ID: 27155213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 blockade: tocilizumab in psoriatic arthritis.
    Atzeni F; Ventura D; Batticciotto A; Boccassini L; Sarzi-Puttini P
    J Rheumatol Suppl; 2012 Jul; 89():97-9. PubMed ID: 22751605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Poddubnyy D; Rudwaleit M
    Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.
    Costa L; Caso F; Cantarini L; Del Puente A; Scarpa R; Atteno M
    Clin Rheumatol; 2014 Sep; 33(9):1355-7. PubMed ID: 24705820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalassemic trait prevalence in patients affected by psoriatic arthritis in anti-TNF treatment.
    Atteno M; Costa L; Vitiello M; Caso F; Sarnelli G; Del Puente A; Scarpa R
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S20-2. PubMed ID: 25381968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
    Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week).
    Nanke Y; Kobashigawa T; Sugimoto N; Yamanaka H; Kotake S
    Immunol Med; 2019 Jun; 42(2):99-102. PubMed ID: 31446856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.